Mumbai (Maharashtra) [India], October 26 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed-dose combination (FDC) of its novel, patent-protected, globally researched Sodium-Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, with Metformin (first-line medication for the treatment of type 2 diabetes).
Mumbai (Maharashtra) [India], October 26 (ANI): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed drug combination for the management of type 2 diabetes.
\
\
\
\
